Veralox
acquired by Cadrenal Therapeutics11 known investors
Find your way into Veralox
Sign up to see every warm intro you have to Veralox
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Veralox team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Acquired by Cadrenal Therapeutics, Inc. December 2025 · $200K ($200,000 at closing plus assumed liabilities and contingent milestone/royalty payments) · source ↗
Developing novel treatments based on the 12-LOX pathway for immuno-inflammatory diseases.
Investors · 11
How we know: av.vc · Not right? Tell us
How we know: Hatteras Venture Partners's portfolio page · a partner's Signal profile · funding news · prnewswire.com · the VCSheet dataset · Not right? Tell us
How we know: Pappas Capital's portfolio page · Not right? Tell us
How we know: Sanofi Ventures's portfolio page · funding news · prnewswire.com · Not right? Tell us
How we know: funding news · prnewswire.com · Not right? Tell us
How we know: funding news · prnewswire.com · Not right? Tell us
How we know: funding news · prnewswire.com · Not right? Tell us
How we know: biobuzz.io · Not right? Tell us
How we know: funding news · biobuzz.io · Not right? Tell us
How we know: funding news · prnewswire.com · Not right? Tell us
How we know: funding news · prnewswire.com · Not right? Tell us
Founder mafia
3 people who came through Veralox went on to found or lead other companies.
Non-dilutive funding · 2 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2020 | $300K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2018 | $319.1K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Veralox do?
- Developing novel treatments based on the 12-LOX pathway for immuno-inflammatory diseases.
- Who are Veralox's investors?
- Veralox's investors include Alumni Ventures, Hatteras Venture Partners, Pappas Capital, Sanofi Ventures, Alexandria, Genesys Capital, JDRF T1D Fund, NYBC Ventures and 3 more.
- Who acquired Veralox?
- Veralox was acquired by Cadrenal Therapeutics.






